Find out what to expect when your
child starts on HUMIRA.
HUMIRA is a prescription medicine used to reduce signs and symptoms, and to achieve and maintain clinical remission in children 6 years of age and older with moderate to severe Crohn’s disease when certain other treatments have not worked well enough.
If the doctor decides that you are able to give your child injections at home, you should receive training by a health care professional on the right way to prepare and inject HUMIRA. Do not try to inject HUMIRA until you have been shown the right way to give the injections.
Your child’s first injection must be given under the supervision of a health care professional.
Remember to keep your HUMIRA refrigerated in its original container until ready for use.
With HUMIRA, making an appointment and traveling to the doctor’s office might not be necessary for every dose. Pens and prefilled syringes of HUMIRA offer you the option to administer your child’s medicine in the comfort of your home. Keeping that in mind, we have the information that you may need to become more familiar with giving your child his or her injection. Your child’s doctor will follow up with you on a regular basis.
We are proud to offer you one-to-one, personalized support from a registered nurse–your own HUMIRA Ambassador. They can assist you in navigating through the insurance process and educate you about our co-pay savings program and other financial assistance that may be available. In addition, a HUMIRA Ambassador can arrange for in-home injection training from a local registered nurse, as well as other tools and services offered by HUMIRA. Call 1.800.4HUMIRA today to enroll in the Ambassador Program (select the option to speak with a nurse).
Learn More About Our HUMIRA Ambassador Program
Do not try to inject HUMIRA yourself until you have been shown the right way to give the injections.
Your child’s first injection must be given under the supervision of a health care professional.
For instructions on the right way to inject HUMIRA, refer to the Patient Instructions for Use for the HUMIRA Pen or HUMIRA prefilled syringe and the Medication Guide for more information. Call your child's doctor if you have any questions about the right way to inject HUMIRA.
Common side effects of HUMIRA include Injection site reactions (redness, rash, swelling, itching, or bruising), upper respiratory infections (sinus infections), headaches, rash, and nausea. These are not all of the possible side effects with HUMIRA. Tell your child’s doctor if he or she is experiencing any side effect that bothers them or that does not go away.
Other injection support
We know that at first, injecting your child might be challenging. With that in mind, we put together step-by-step instructional videos to assist you in learning how to properly inject HUMIRA.
We understand that injecting your child may be a new and unfamiliar experience, but it's a necessary part in keeping up with your child's treatment. Here are some Tips for Creating a Positive Injection Environment you may try that may help the transition into your child's injection routine.
Important: You must pay attention to your child’s starting dose—it is different than his or her maintenance dose and is a critical part of taking HUMIRA as prescribed. The doctor will take
your child's weight into consideration when deciding the appropriate dose. Your child’s first injection must be given under the supervision of a health care professional. Remember to keep HUMIRA refrigerated in its original container until ready for use.
If your child weighs from 37 to 87 lbs
Starting Dose
On Day 1*
Two 40 mg prefilled
syringes (80 mg)
On Day 15
One 40 mg
prefilled syringe
Continuing Dose
On Day 29 and every
other week thereafter
One 20 mg prefilled syringe
If your child weighs 88 lbs or more
Starting Dose
On Day 1†
Four 40 mg prefilled
syringes‡ (160 mg)
On Day 15*
Two 40 mg prefilled
syringes‡ (80 mg)
Continuing Dose
On Day 29 and every
other week thereafter
One 40 mg prefilled syringe‡
* 80 mg dose is given as 2 injections in one day.
† If your child weighs 88 lbs or more, the first dose (160 mg) can be administered as 4 injections in one day or as 2 injections per day for 2 consecutive days.
‡ HUMIRA is also available in 40 mg prefilled Pens.
HUMIRA has not been studied in pediatric patients with Crohn’s disease less than 6 years old.
Some parents may think they can stop their child’s treatment if their child feels better and is experiencing fewer symptoms. However, only your child’s doctor can tell you if and when you should stop giving your child HUMIRA.
If your child experiences any adverse reactions or discomfort when taking HUMIRA, discuss them with the doctor right away.
The HUMIRA Ambassador Program is here to provide education and support for you and your child.
Call 1.800.4HUMIRA to sign up for the HUMIRA Ambassador Program today (select the option to speak with a nurse).
Next Page: HUMIRA Ambassador Program
Your child's safety is important to us.
Learn about our Important Safety Information.
IMPORTANT SAFETY INFORMATION
ABOUT HUMIRA® (adalimumab)1
You should discuss the potential benefits and risks of HUMIRA with your doctor. HUMIRA is a TNF blocker medicine that can lower the ability of your immune system to fight infections. You should not start taking HUMIRA if you have any kind of infection unless your doctor says it is okay.
-
Serious infections have happened in people taking HUMIRA. These serious infections include tuberculosis (TB) and infections caused by viruses, fungi, or bacteria that have spread throughout the body. Some people have died from these infections. Your doctor should test you for TB before starting HUMIRA, and check you closely for signs and symptoms of TB during treatment with HUMIRA, even if your TB test was negative. If your doctor feels you are at risk, you may be treated with medicine for TB.
-
Cancer. For children and adults taking TNF blockers, including HUMIRA, the chance of getting lymphoma or other cancers may increase. There have been cases of unusual cancers in children, teenagers, and young adults using TNF blockers. Some people have developed a rare type of cancer called hepatosplenic T-cell lymphoma. This type of cancer often results in death. If using TNF blockers including HUMIRA, your chance of getting two types of skin cancer (basal cell and squamous cell) may increase. These types are generally not life-threatening if treated; tell your doctor if you have a bump or open sore that doesn’t heal.
Tell your doctor about all of your health conditions, including if you:
- Have an infection, are being treated for infection, or have symptoms of an infection
- Get a lot of infections or infections that keep coming back
- Have diabetes
- Have TB or have been in close contact with someone with TB, or were born in, lived in, or traveled where there is more risk for getting TB
- Live or have lived in an area (such as the Ohio and Mississippi River valleys) where there is an increased risk for getting certain kinds of fungal infections, such as histoplasmosis, coccidioidomycosis, or blastomycosis. These infections may happen or become more severe if you use HUMIRA. Ask your doctor if you are unsure if you have lived in these areas.
- Have or have had hepatitis B
- Are scheduled for major surgery
- Have or have had cancer
- Have numbness or tingling or a nervous system disease such as multiple sclerosis or Guillain-Barré syndrome
- Have or had heart failure
- Have recently received or are scheduled to receive a vaccine. HUMIRA patients may receive vaccines, except for live vaccines. Children should be brought up to date on all vaccines before starting HUMIRA.
- Are allergic to rubber, latex, or any HUMIRA ingredients
- Are pregnant, planning to become pregnant, breastfeeding, or planning to breastfeed
- Have a baby and you were using HUMIRA during your pregnancy. Tell your baby’s doctor before your baby receives any vaccines
Also tell your doctor about all the medicines you take. You should not take HUMIRA with ORENCIA® (abatacept), KINERET® (anakinra), REMICADE® (infliximab), ENBREL® (etanercept), CIMZIA® (certolizumab pegol), or SIMPONI® (golimumab). Tell your doctor if you have ever used RITUXAN® (rituximab), IMURAN® (azathioprine), or PURINETHOL® (mercaptopurine, 6-MP).
HUMIRA can cause serious side effects, including:
- Serious infections. These include TB and infections caused by viruses, fungi, or bacteria. Symptoms related to TB include a cough, low-grade fever, weight loss, or loss of body fat and muscle.
- Hepatitis B infection in carriers of the virus. Symptoms include muscle aches, feeling very tired, dark urine, skin or eyes that look yellow, little or no appetite, vomiting, clay-colored bowel movements, fever, chills, stomach discomfort, and skin rash.
- Allergic reactions. Symptoms of a serious allergic reaction include hives, trouble breathing, and swelling of your face, eyes, lips, or mouth.
- Nervous system problems. Signs and symptoms include numbness or tingling, problems with your vision, weakness in your arms or legs, and dizziness.
- Blood problems (decreased blood cells that help fight infections or stop bleeding). Symptoms include a fever that does not go away, bruising or bleeding very easily, or looking very pale.
- Heart failure (new or worsening). Symptoms include shortness of breath, swelling of your ankles or feet, and sudden weight gain.
- Immune reactions including a lupus-like syndrome. Symptoms include chest discomfort or pain that does not go away, shortness of breath, joint pain, or rash on your cheeks or arms that gets worse in the sun.
- Liver problems. Symptoms include feeling very tired, skin or eyes that look yellow, poor appetite or vomiting, and pain on the right side of your stomach (abdomen).
- Psoriasis (new or worsening). Symptoms include red scaly patches or raised bumps that are filled with pus.
Call your doctor or get medical care right away if you develop any of the above symptoms.
Common side effects of HUMIRA include injection site reactions (redness, rash, swelling, itching, or bruising), upper respiratory infections (sinus infections), headaches, rash, and nausea. These are not all of the possible side effects with HUMIRA. Tell your doctor if you have any side effect that bothers you or that does not go away.
- Fever, sweats, or chills
- Muscle aches
- Cough
- Shortness of breath
- Blood in phlegm
- Weight loss
- Warm, red, or painful skin or sores on your body
- Diarrhea or stomach pain
- Burning when you urinate
- Urinating more often than normal
- Feeling very tired
HUMIRA is given by injection under the skin.
HUMIRA is a prescription medicine used:
- To reduce the signs and symptoms of:
- Moderate to severe rheumatoid arthritis (RA) in adults. HUMIRA can be used alone, with methotrexate, or with certain other medicines. HUMIRA may prevent further damage to your bones and joints and may help your ability to perform daily activities.
- Moderate to severe polyarticular juvenile idiopathic arthritis (JIA) in children 2 years of age and older. HUMIRA can be used alone, with methotrexate, or with certain other medicines.
- Psoriatic arthritis (PsA) in adults. HUMIRA can be used alone or with certain other medicines. HUMIRA may prevent further damage to your bones and joints and may help your ability to perform daily activities.
- Ankylosing spondylitis (AS) in adults.
- Moderate to severe Crohn's disease (CD) and to achieve and maintain clinical remission in adults who have not responded well to certain other medications. HUMIRA is also used to reduce signs and symptoms and to achieve clinical remission in these adults who have lost response to or are unable to tolerate infliximab.
- Moderate to severe Crohn's disease (CD) and to achieve and maintain clinical remission in children 6 years of age and older when certain other treatments have not worked well enough.
- Moderate to severe hidradenitis suppurativa (HS) in adults.
- In adults, to help get moderate to severe ulcerative colitis (UC) under control (induce remission) and keep it under control (sustain remission) when certain other medicines have not worked well enough. It is not known if HUMIRA is effective in people who stopped responding to or could not tolerate anti-TNF medicines.
- To treat moderate to severe chronic plaque psoriasis (Ps) in adults who are ready for systemic therapy or phototherapy, and are under the care of a doctor who will decide if other systemic therapies are less appropriate.
- To treat non-infectious intermediate (middle part of the eye), posterior (back of the eye) and panuveitis (all parts of the eye) (UV) in adults.
64H-1880706
Moderate to Severe Rheumatoid Arthritis
Moderate to Severe Chronic Plaque Psoriasis
Moderate to Severe Crohn's Disease
Moderate to Severe Pediatric Crohn's Disease
Moderate to Severe Ulcerative Colitis
Psoriatic Arthritis
Moderate to Severe Hidradenitis Suppurativa
Ankylosing Spondylitis
Moderate to Severe Polyarticular
Non-Infectious Intermediate, Posterior,
